Impella 5.0: An intermediate strategy for bridging a patient from infected durable LVAD to cardiac transplant.

J Card Surg

Division of Cardiothoracic and Vascular Surgery, Heart Transplant, Mechanical Circulatory Support and ECMO, Lutheran Hospital, Indiana University School of Medicine - Fort Wayne (IUSM-FW), Fort Wayne, Indiana, USA.

Published: March 2022

Cardiac transplant remains the gold-standard treatment for end-stage heart failure more than 50 years after the procedure was first pioneered. The number of transplant operations performed annually has been limited by the global imbalance of donor organs to recipients. This imbalance helped fuel the development of left ventricular assist devices (LVADs) first as a bridge to cardiac transplant and subsequently as destination therapy. Driveline infection is one of several problems that continue to plague LVADs through several generations of improvement. We present a patient with an infected LVAD driveline exit site that progressed to mediastinitis, pericardial and pump infection. The device was explanted, and the patient supported with an axillary Impella 5.0 as a bridge until the time of transplant. An Impella 5.0 (or 5.5) can be used as an intermediate tool to be able to explant an infected LVAD, with mediastinitis, allowing the patient to clear the infection, and prepare the patient for transplant free of infection. METHODS: The patient consented to the study and case report. The patient signed an informed consent and permission for publication.

Download full-text PDF

Source
http://dx.doi.org/10.1111/jocs.16186DOI Listing

Publication Analysis

Top Keywords

cardiac transplant
12
impella intermediate
8
patient infected
8
infected lvad
8
patient
7
transplant
6
intermediate strategy
4
strategy bridging
4
bridging patient
4
infected durable
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!